Immuno-inflammatory and organ dysfunction markers in severe COVID-19 patients

被引:0
|
作者
Ahmed, Najat Jabbar [1 ]
Amin, Zahra A. [2 ]
Kheder, Ramiar Kamal [3 ,4 ]
Pirot, Rzgar Qadir [5 ]
Mutalib, Gulstan A. [1 ]
Jabbar, Sana Najat [1 ]
机构
[1] Erbil Polytech Univ, Erbil Tech Hlth & Med Coll, Dept Med Lab Technol, Erbil 44001, Iraq
[2] Hawler Med Univ, Coll Pharm, Dept Clin Anal, Erbil 44001, Iraq
[3] Univ Raparin, Coll Sci, Med Lab Sci Dept, Rania 46012, Sulaymaniyah, Iraq
[4] Tishk Int Univ, Fac Appl Sci, Dept Med Anal, Erbil, Iraq
[5] Univ Raparin, Coll Sci, Biol Dept, Rania 46012, Sulaymaniyah, Iraq
关键词
SARS CoV-2; Cytokine; Inflammation; Biomarkers; Body organs; COUNT;
D O I
10.1016/j.cyto.2024.156715
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Infection with the SARS-CoV-2 virus may induce some complications among people who experience mild to moderate respiratory illness and some of them recover without requiring special treatment. Albeit, some individuals become seriously reached risk points and require special medical attention especially older people and people who suffer from chronic diseases. Serum and whole blood samples were collected from confirmed infected persons with SARS CoV-2 by real-time PCR and the control group. All lab. Investigations were performed using Cobas 6000. Significant differences were noted between patients compared to the control group in the Mean f SD of IL-6 (76.06 f 7.60 vs 3.61 f 0.296 pg/ml), Procalcitonin (0.947 f 0.117 vs 0.061 f 0.007 ng/ml), CRP (125.3 f 7.560 vs 4.027 f 0.251 mg/dl), ALT (154.8 f 30.47 vs 49.75 f 2.977 IU/L) and AST (70.83 f 9.215 vs 27.23 f 1.767) respectively. While other parameters were also showed significant differences were noted between patients compared to the control group for D-Dimmer, PT, PTT, LDH, Ferritin, WBC, Lymphocyte and Creatinine. The results reached that the effect of SARS CoV-2 and cytokine storm was clear on the body's organs through vital biomarker investigations that were performed in this study.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Coagulopathy of Patients with COVID-19 is Associated with Infectious and Inflammatory Markers
    Long, Xin
    Zhang, Zhanguo
    Zou, Wenbin
    Ling, Jianmin
    Li, Donghui
    Jing, Liang
    Yu, Shanshan
    Zou, Xiaojing
    Bian, Yi
    Wu, Wenjuan
    Li, Shusheng
    Fang, Minghao
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2020, 13 : 1965 - 1974
  • [22] PRO-INFLAMMATORY MARKERS IN COVID-19 PATIENTS WITH HYPERTENSION
    Andhika, Rizky
    Supriyadi, Rudi
    Alisjahbana, Bachti
    JOURNAL OF HYPERTENSION, 2021, 39 : E6 - E7
  • [23] ASSOCIATION BETWEEN BMI AND INFLAMMATORY MARKERS IN COVID-19 PATIENTS
    Mendez-Castro, Jesus
    Castro, Juan ManuelMendez
    Mariana Ramirez, Luz
    Said, Mohamed Ziad-M.
    Villalobos, Ana
    Molina, Paloma
    Texidor, Jovana
    Terrazas, Andrea
    Canto-Costal, Ana Cecilia
    Mongo, Joel
    Mathew, Joan
    Patron, Daniel
    Aguilar, Isaac
    Figueroa, Rene
    Sammyghaou
    Josephvaron
    CRITICAL CARE MEDICINE, 2024, 52
  • [24] Impact of comorbidities and inflammatory markers on mortality of COVID-19 patients
    Karim, Azmat
    Shameem, Mohammad
    Talwar, Anjana
    Talwar, Deepak
    LUNG INDIA, 2024, 41 (01) : 40 - 46
  • [25] THE DYNAMICS OF INFLAMMATORY MARKERS IN COVID-19 PATIENTS TREATED WITH LEVILIMAB
    Lomakin, N.
    Bakirov, B.
    Musaev, G.
    Protsenko, D.
    Moiseeva, O.
    Pasechnik, E.
    Popov, V.
    Smolyarchuk, E.
    Gordeev, I.
    Gilyarov, M.
    Fomina, D.
    Mazurov, V.
    Morozova, M.
    Dokukina, E.
    Bogdan, D.
    Lutskii, A.
    Zinkina-Orihan, A.
    Linkova, I.
    Seleznev, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 890 - 891
  • [26] The effect of tocilizumab administration on inflammatory markers in COVID-19 patients
    Soliman, Engy Mohamed Riyad
    Wageh, Khaled Mohamed
    Mohamed, Mahmoud Mokhtar
    Mohamed, Hoda Attiatullah
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2024, 18 (01)
  • [27] INFLAMMATORY MARKERS IN GYNECOLOGIC ONCOLOGY PATIENTS HOSPITALIZED WITH COVID-19
    Smith, M.
    Lara, O.
    O'Cearbhaill, R.
    Sutter, M.
    Knisely, A.
    McEachron, J.
    Gabor, L.
    Carr, C.
    Blank, S.
    Prasad-Hayes, M.
    Frey, M.
    Jee, J.
    Fehniger, J.
    Lee, Y. C.
    Isani, S.
    Wright, J.
    Pothuri, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A120 - A120
  • [28] Prognostic value of inflammatory markers in patients with COVID-19 in Indonesia
    Prasetya, Ignatius Bima
    Cucunawangsih
    Lorens, Jane Olivia
    Sungono, Veli
    El-Khobar, Korri Elvanita
    Wijaya, Ratna Sari
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2021, 11
  • [29] Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab
    Pastina, Pierpaolo
    Nardone, Valerio
    Giuseppe, Battaglia
    Botta, Cirino
    Tini, Paolo
    Bellan, Cristiana
    Ricci, Veronica
    Barbarino, Marcella
    Croci, Stefania
    Caraglia, Michele
    Giordano, Antonio
    Cusi, Maria Grazia
    Pirtoli, Luigi
    Correale, Pierpaolo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S921 - S921
  • [30] Immune dysfunction following COVID-19, especially in severe patients
    Song, Cong-Ying
    Xu, Jia
    He, Jian-Qin
    Lu, Yuan-Qiang
    SCIENTIFIC REPORTS, 2020, 10 (01)